Do oncogenes determine clinical features in chronic myeloid leukaemia?
Do oncogenes determine clinical features in chronic myeloid leukaemia?
复制标题
癌基因决定慢性粒细胞白血病的临床特征吗？
DOI：
10.1016/s0140-6736(87)90594-0
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
Gale,RP
中科院分区：
文献类型：
--
作者：
Dreazen,O;Klisak,I;Rassool,F;Goldman,JM;Sparkes,RS;Gale,RP
癌基因异常被认为在一些人类恶性疾病中具有核心作用，特别是伯基特白血病/淋巴瘤和慢性髓性白血病（CML）。然而，特定的癌基因变化在多大程度上决定这些疾病的临床特征是未知的。这个问题在两组Ph染色体阴性的CML患者中进行了研究;一组表现出Ph阳性CML的典型临床特征，另一组缺乏这些特征。并与Ph阳性CML的分子生物学结果进行比较。在所有10例患者中，有证据表明bcr（断点簇区）基因重排。在研究的4例c-abl原癌基因易位到22号染色体，在5例有一个嵌合bcr-abl mRNA的转录。因此，分子异常在两组Ph阴性CML中是相同的，并且与Ph阳性CML相同。除了bcr/c-ab重排以外的其他因素也是CML临床异质性的基础。
Oncogene abnormalities are thought to have a central role in some human malignant disorders, particularly Burkitt leukaemia/ lymphoma and chronic myeloid leukaemia (CML). However, the extent to which specific oncogene changes determine the clinical features of these disorders is unknown. This question was studied in two groups of patients with CML negative for the Philadelphia (Ph) chromosome; one group showed clinical features typical of Ph-positive CML and the other group lacked such features. Molecular findings were compared with those of Ph-positive CML. In all ten patients there was evidence for rearrangement of thebcr(breakpoint cluster region) gene. In the four cases studied the c-ablproto-oncogene was translocated to chromosome 22 and in five cases there was transcription of a chimericbcr-ablmRNA. Thus, the molecular abnormality is the same in both groups of Ph-negative CML and identical to that in Ph-positive CML. Factors other than thebcr/c-ablrearrangement must underlie the clinical heterogeneity of CML.